| Sophie Fletcher, MD | |
|
6560 Fannin, Suite 2100, Houston, TX 77030 | |
| (713) 798-4637 | |
| Not Available |
| Full Name | Sophie Fletcher |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 6560 Fannin, Houston, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093924714 | NPI | - | NPPES |
| 8BZ370 | Other | TX | BLUE CROSS BLUE SHIELD |
| P00968054 | Other | TX | RR MEDICARE |
| P01063001 | Other | TX | RAILROAD MEDICARE |
| 186632904 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | M6132 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sutter Santa Rosa Regional Hospital | Santa rosa, CA | Hospital |
| California Pacific Medical Ctr-davies Campus Hosp | San francisco, CA | Hospital |
| Sutter Lakeside Hospital | Lakeport, CA | Hospital |
| Adventist Health Ukiah Valley | Ukiah, CA | Hospital |
| Santa Rosa Memorial Hospital | Santa rosa, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease.
In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
› Verified 9 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease.
In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sophie Fletcher, MD 6560 Fannin, Suite 2100, Houston, TX 77030 Ph: (713) 798-4637 | Sophie Fletcher, MD 6560 Fannin, Suite 2100, Houston, TX 77030 Ph: (713) 798-4637 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease.
In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
› Verified 9 days ago
Guilherme Godoy, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 6620 Main St, Suite 1325, Ms Bcm380, Houston, TX 77030 Phone: 713-798-5628 Fax: 713-798-5553 | |
Kelly Bree, M.D. Urology Medicare: Medicare Enrolled Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Prof. Peter Phuc Hinh, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1200 Binz St Ste 690, Houston, TX 77004 Phone: 713-366-7831 Fax: 713-482-5815 | |
Dr. Herbert L Watkins, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1140 Westmont Dr Ste 425, Houston, TX 77015 Phone: 713-453-4395 Fax: 713-453-4397 | |
Dr. Kumaran Sathyamoorthy, MD, MPH Urology Medicare: Accepting Medicare Assignments Practice Location: 10425 Huffmeister Rd Ste 210, Houston, TX 77065 Phone: 281-890-0911 Fax: 281-890-0980 | |
Kevin G Nickell, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 7777 Southwest Fwy, # 1032, Houston, TX 77074 Phone: 713-351-0644 Fax: 713-351-0633 | |
Richard J. Babaian, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 |